

Pharmacy and Therapeutics (P&T) Committee Meeting
February 16, 2016
AGENDA

- | | |
|---|-------------------|
| I. Welcome | David Boerner, MD |
| II. Introductions | Adam Root, PharmD |
| III. Conflict of Interest Statement | Adam Root, PharmD |
| IV. Minutes from November 17, 2015 meeting | Adam Root, PharmD |
| V. Old Business | |
| ➤ PA program updates | Adam Root, PharmD |
| ➤ Nucala Policy | David Boerner, MD |
| VI. Light meal | |

Executive Session (Closed to members only)

VII. Program Reviews and Opportunities

- | | |
|-------------------|--|
| ➤ Stivarga Policy | Michael Spiritos, MD |
| ➤ Lonsurf Policy | Michael Spiritos, MD |
| ➤ Cotellic Policy | Michael Spiritos, MD |
| ➤ Keveyis Policy | David Konanc, MD |
| ➤ Daraprim Policy | Adam Root, Pharm D or
David Boerner, MD |

VIII. New Drug Reviews

Information to consider when recommending Must Add, May Add, and Must Not Add Status

- | | |
|--|------------------------|
| ➤ Synjardy® (empagliflozin/metformin HCL tablet –Boehringer Ingelheim) | Jennifer Smith, PharmD |
| ➤ Tresiba® (insulin degludec – NovoNordisk) | Jennifer Burch, PharmD |
| ➤ Viberzi™ (eluxadoline tablet – Actavis) | Kenneth Kohagen, MD |
| ➤ Envarus XR® (tacrolimus extended-release tablet – Veloxis) | David Boerner, MD |
| ➤ Vraylar™ (cariprazine capsule – Allergan) | Randy Grigg, MD |

- Tolak® (fluorouracil 4% cream – Hill Dermaceuticals)

Matthew Flynn, MD

IX. Other Topics

- Medical to Specialty Update
- Specialty Generic Tier

Sandy Wolf
Sandy Wolf

Next meeting date: May 10, 2016

2016 meeting dates

May 10, 2016
August 9, 2016
November 8, 2016